Sign in

CIK 0001528115

  • Non-accelerated filer
  • Smaller reporting company

Annexon, Inc.

Sign in to watch
Ticker
ANNX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
275414423
Phone
+1 650-822-5500
Business address
1400 SIERRA POINT PARKWAY, BLDG C, SUITE 200, BRISBANE, CA, 94005
  1. 4 Open-market buy President & CEO bought 60,000 shares at $2.45 ($146,814)
  2. 4 Grant or award President & CEO acquired 40,000 shares (grant or award)
  3. 4 Grant or award EVP & Chief Business Officer acquired 12,500 shares (grant or award)
  4. 4 Grant or award EVP & Chief Medical Officer acquired 12,500 shares (grant or award)
  5. 4 Grant or award EVP & Chief Financial Officer acquired 12,500 shares (grant or award)
  6. 4 Grant or award EVP & Chief Scientific Officer acquired 12,500 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 3 Insider Initial Statement of Ownership
  9. 4 Option exercise President & CEO acquired 100,942 shares (option exercise)
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Open-market sale President & CEO sold 7,500 shares at $22.05 ($165,341)
  13. 4 Open-market sale EVP & Chief Scientific Officer sold 16,190 shares at $20.00 ($323,860)
  14. 4 Open-market sale EVP & Chief Financial Officer sold 3,500 shares at $20.01 ($70,034)
  15. 4 Derivatives Options or other derivatives
  16. 3 Insider Initial Statement of Ownership
  17. 4 Open-market sale President & CEO sold 7,500 shares at an average $22.43 ($168,230)
  18. 4 Open-market sale EVP & Chief Scientific Officer sold 15,000 shares at an average $21.49 ($322,325)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 8 of 11 · 206 filings